La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BioRem Salute del bilancio

Salute finanziaria criteri di controllo 5/6

BioRem ha un patrimonio netto totale di CA$7.4M e un debito totale di CA$2.8M, che porta il suo rapporto debito/patrimonio netto a 38.5%. Le sue attività totali e le sue passività totali sono rispettivamente CA$22.1M e CA$14.7M. L'EBIT di BioRem è CA$4.5M rendendo il suo rapporto di copertura degli interessi 17.1. Ha liquidità e investimenti a breve termine pari a CA$5.9M.

Informazioni chiave

38.5%

Rapporto debito/patrimonio netto

CA$2.84m

Debito

Indice di copertura degli interessi	17.1x
Contanti	CA$5.90m
Patrimonio netto	CA$7.37m
Totale passività	CA$14.69m
Totale attività	CA$22.06m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

Apr 19

BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

Apr 12

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Jan 25

Is BioRem (CVE:BRM) Using Too Much Debt?

Aug 26

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

Mar 23

BioRem (CVE:BRM) Could Easily Take On More Debt

Aug 25

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

May 20

Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Jan 26

Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

Nov 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CA$18.4M ) di BRM superano le sue passività a breve termine ( CA$11.4M ).

Passività a lungo termine: Le attività a breve termine di BRM ( CA$18.4M ) superano le sue passività a lungo termine ( CA$3.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BRM ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di BRM è aumentato da 0% a 38.5% negli ultimi 5 anni.

Copertura del debito: Il debito di BRM è ben coperto dal flusso di cassa operativo ( 129.2% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di BRM sono ben coperti dall'EBIT ( 17.1 x copertura).

BioRem Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Is BioRem (CVE:BRM) Using Too Much Debt?

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

BioRem (CVE:BRM) Could Easily Take On More Debt

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

Recent updates

First quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.036 loss in 1Q 2023)

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

BioRem Inc., Annual General Meeting, Jun 04, 2024

BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

Full year 2023 earnings released: EPS: CA$0.14 (vs CA$0.10 in FY 2022)

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Investor sentiment improves as stock rises 39%

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.049 in 3Q 2022)

Insufficient new directors

Is BioRem (CVE:BRM) Using Too Much Debt?

New minor risk - Share price stability

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.011 profit in 2Q 2022)

Insufficient new directors

Investor sentiment improves as stock rises 20%

First quarter 2023 earnings released: CA$0.036 loss per share (vs CA$0.007 loss in 1Q 2022)

Full year 2022 earnings released: EPS: CA$0.10 (vs CA$0.036 in FY 2021)

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

Third quarter 2022 earnings released: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021)

BioRem (CVE:BRM) Could Easily Take On More Debt

Second quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.007 in 2Q 2021)

First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 1Q 2021)

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

BIOREM Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: EPS: CA$0.036 (vs CA$0.054 in FY 2020)

Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Third quarter 2021 earnings: Revenues in line with analyst expectations

BIOREM Inc. (TSXV:BRM) announces an Equity Buyback for 23,434,121 shares, for CAD 12.32 million.

High number of new directors

Second quarter 2021 earnings released: EPS CA$0.007 (vs CA$0.009 in 2Q 2020)

High number of new directors

First quarter 2021 earnings released: EPS CA$0.01 (vs CA$0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.05 (vs CA$0.034 loss in FY 2019)

BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.64

BIOREM Inc. Announces Research Project with City of New York to Control Release of Bioaerosols from Waste Water Treatment Facilities

New 90-day high: CA$0.58

BIOREM Inc. Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC Emissions

Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

New 90-day high - CA$0.39

Earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane